J&J, 2 Ohio counties reach $20M opioid settlement

Johnson & Johnson has agreed to pay $20.4 million to avoid the first federal trial that accuses the drugmaker of fueling the opioid epidemic.

Advertisement

Under the deal, J&J will pay two Ohio counties, Cuyahoga and Summit, $10 million in cash and $5 million to cover legal expenses. J&J will also donate $5.4 million to groups fighting the opioid epidemic in the state. 

The company said the settlement allows it “to avoid the resource demands and uncertainty of a trial as it continues to seek meaningful progress in addressing the nation’s opioid crisis.”

This marks the first time J&J has settled an opioid-related lawsuit, according to Bloomberg. Earlier this year, the company lost when it fought allegations in Oklahoma that it illegally marketed its opioid drugs. A judge ordered the drugmaker to pay $572 million.

J&J is the fourth drugmaker to settle ahead of a bellwether trial set to begin Oct. 21 in Cleveland. Drugmakers Mallinckrodt, Endo International and Allergan also have made settlements. Purdue Pharma’s settlement, which includes a bankruptcy filing, is pending.

More articles on pharmacy:
Following CVS, Walgreens and Rite Aid pull Zantac from shelves
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.